

SCIENTIFIC REPORTS



OPEN

RNA-Seq transcriptome profiling of mouse oocytes after *in vitro* maturation and/or vitrification

Lei Gao¹, Gongxue Jia², Ai Li³, Haojia Ma¹, Zhengyuan Huang¹, Shien Zhu¹, Yunpeng Hou⁴ & Xiangwei Fu¹

In vitro maturation (IVM) and vitrification have been widely used to prepare oocytes before fertilization; however, potential effects of these procedures, such as expression profile changes, are poorly understood. In this study, mouse oocytes were divided into four groups and subjected to combinations of *in vitro* maturation and/or vitrification treatments. RNA-seq and *in silico* pathway analysis were used to identify differentially expressed genes (DEGs) that may be involved in oocyte viability after *in vitro* maturation and/or vitrification. Our results showed that 1) 69 genes were differentially expressed after IVM, 66 of which were up-regulated. *Atp5e* and *Atp5o* were enriched in the most significant gene ontology term “mitochondrial membrane part”; thus, these genes may be promising candidate biomarkers for oocyte viability after IVM. 2) The influence of vitrification on the transcriptome of oocytes was negligible, as no DEGs were found between vitrified and fresh oocytes. 3) The MII stage is more suitable for oocyte vitrification with respect to the transcriptome. This study provides a valuable new theoretical basis to further improve the efficiency of *in vitro* maturation and/or oocyte vitrification.

In vitro maturation (IVM) of mammalian oocytes is an essential technique used in research of developmental biology and assisted reproductive technology (ART)¹. However, oocytes matured *in vitro* are of lower quality than those matured *in vivo*. Embryos from oocytes matured *in vitro* have decreased preimplantation embryo development, low pregnancy rates and poor live birth indexes². Moreover, knowledge about the low efficiency of IVM is poor compared to *in vivo* maturation, which limits the further development of IVM techniques³. A comparison of the different features of oocytes matured *in vitro* or *in vivo* via transcriptome analyses provides an opportunity to identify oocyte competence biomarkers. A study of human oocytes using microarrays has provided further insight into alterations that occur during maturation⁴; however, the suboptimal quality of the material (oocytes failed to fertilize) makes it difficult to interpret the conclusions. The differences in transcriptome profiles between *in vivo* and *in vitro* matured oocytes still require further investigation.

Oocyte cryopreservation can preserve excess oocytes obtained during treatment, averting repeated oocyte retrieval from the patients⁵. Oocyte cryopreservation can also preserve fertility in women who may lose their ovarian function because of surgery, cancer treatment, or premature menopause⁶ and in women who decide to postpone having children due to socioeconomic pressures⁷. In addition, human embryo cryopreservation is prohibited in some countries (e.g. Italy)⁸. Thus, for this case, oocyte cryopreservation could be the optimal choice to preserve fertility rather than embryo cryopreservation.

As an efficient and convenient method of cryopreservation, vitrification is now widely used. However, high concentrations of cryoprotective agents as well as chilling injury may affect the ultrastructure, such as the spindles and chromosomes⁹, and the mitochondrial function¹⁰ of the oocytes. Mitochondrial function can be reflected by the ratio of flavin adenine dinucleotide/ reduced nicotinamide adenine dinucleotide phosphate (the ratio of FAD/NAD(P)H) which is an established method for monitoring relative amounts of electron donor and acceptor in a

¹National Engineering Laboratory for Animal Breeding and Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing, 100193, P.R. China. ²Key Laboratory of Adaptation and Evolution of Plateau Biota, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, 810001, P.R. China. ³Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing, 100193, P.R. China. ⁴State Key Laboratory for Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing, 100193, P.R. China. Lei Gao and Gongxue Jia contributed equally to this work. Correspondence and requests for materials should be addressed to X.F. (email: xiangweifufu@126.com)




Figure 1. Experimental design and gene expression levels in the four groups. The figure (a) shows the experimental design. The boxplot (b) shows the gene expression level (\log_{10} FPKM) in each sample. (c) shows the results of a clustering analysis of gene expression levels (FPKM) in each sample.

cell. An increased ratio of FAD/NAD(P)H suggests a decreased ATP level in vitrified human metaphase II (MII, the second stage in meiosis II after prophase II) stage oocytes^{10,11}, which significantly affects spindle integrity and chromosome alignment¹². There are also other factors that may influence the cryopreservation efficiency of oocytes, in particular the development stage of the oocytes. For example, one major problem of MII stage oocytes is the sensitivity of the spindles to low temperatures and cryoprotective agents^{13–15}. Theoretically, this damage can be avoided by vitrification of the germinal vesical (GV) stage oocytes, a stage when the spindle apparatus has not yet formed. However, oocytes vitrified in the GV stage must go through IVM after thawing, which may further influence oocyte competence. There are reports of babies born from oocytes vitrified at both of these two stages^{16–18}; however, the molecular mechanism underlying which stage is more suitable for oocyte vitrification is still unclear.

In this study, RNA-seq was used to analyse the transcriptomes of differently treated mouse MII stage oocytes to gain a better understanding of the transcriptome events in the oocytes after *in vitro* maturation and/or vitrification. The following four groups of mouse MII stage oocytes were used: 1. fresh GV stage oocytes matured *in vitro* (FG); 2. vitrified GV stage oocytes matured *in vitro* (VG); 3. fresh MII stage oocytes matured *in vivo* (FM); 4. vitrified MII stage oocytes matured *in vivo* (VM) (Fig. 1a). We also performed a Gene Ontology (GO) analysis of the differentially expressed genes. Our results contribute to the understanding of the transcriptional regulatory mechanisms of oocytes undergoing *in vitro* maturation and/or vitrification and offer a theoretical basis to further improve the efficiency of the *in vitro* maturation and/or vitrification of oocytes. This study also provided a transcriptional basis for using oocyte vitrification to preserve female fertility for those who may lose their ovarian function because of surgery, cancer treatment and premature menopause or who decide to postpone having children.

Results

Summary of RNA-Seq data quality. We performed RNA-seq to analyse the transcriptomes of MII stage mouse oocytes from different groups, including FG, VG, FM and VM (Fig. 1a). Approximately 532 million reads (82.99% of clean reads) mapped to the reference genome and 79.83% were uniquely mapped (Table S1). The expression of each transcript in each sample was measured as the expected number of fragments per kilobase of transcript sequence per millions base pairs sequenced (FPKM). Genes with values of FPKM >1 were considered to be genes expressed in this study. Boxplots of \log_{10} -transformed FPKM values for each replicate showed that the overall range and distribution of the FPKM values were consistent among the samples (Fig. 1b). R^2 values




Figure 2. Oocytes matured *in vitro* influence the genes expression of mitochondrial membrane protein. The Volcano plot (a) shows differentially expressed genes meeting the conditions of adjusted P -value < 0.05 . Red dots represent the 66 genes up-regulated in FG vs. FM, green dots represent 3 genes down-regulated in FG vs. FM, and blue dots represent the genes that were not differentially expressed in FG vs. FM. (b) we included the most significant GO categories affected by *in vitro* maturation (FG vs. FM) based on adjusted p -values. Red represents terms relating to biological processes, green represents terms relating to cellular components and blue represents terms relating to molecular function. The number of genes in each term is shown to the right of the pillar. (c) *Atp5e* and *Atp5o* were randomly selected and examined by qRT-PCR. The expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data. Cyan represents FG group, red represents FM group.

were between 0.889 and 0.978 for all three replicates within the four groups, thus indicating that there were no significant differences in gene expression among the biological replicates (Figure S1). These results indicated that our RNA-seq data was reliable, reproducible and of high quality. Cluster analysis also showed that differences occurred among the four samples, thus confirming that our RNA-seq data met the conditions for differential expression analysis (Fig. 1c).

***In vitro* maturation influence the genes expression of mitochondrial membrane protein.** To analyse the effects of *in vitro* maturation on gene expression in MII stage oocytes, we compared the gene expression profiles of FG with FM. Genes with FPKM > 1 and adjusted p -value < 0.05 were considered to represent significant DEGs (differentially expressed genes) and that was also the case for similarly analysed data throughout this study. In total, 69 DEGs were identified (Table S2): 66 up-regulated and 3 down-regulated (Fig. 2a). GO enrichment analysis was performed to investigate which biological functions were important after IVM on 48 annotated DEGs of 69 total DEGs. “Mitochondrial membrane part” was the significant enrichment term in cellular components category, which involved 8 DEGs, including *Atp5e*, *Atp5o*, *Cox4i1*, *Cox7b*, *Ndufa5*, *Ndufb9*, *Ndufs7* and *Uqcrcq*; “hydrogen ion transmembrane transport and activity” was the most significant enrichment term in biological processes category (Fig. 2b), which included 5 genes: *Atp5e*, *Atp5o*, *Cox4i1*, *Cox7b* and *Uqcrcq* (Table S3). Interestingly, *Atp5e* and *Atp5o* were involved in both significant terms and occurred in the top 10 significant DEGs (Table S2). *Atp5e* and *Atp5o* were randomly selected and examined using qRT-PCR. The expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data (Fig. 2c).

Vitrification has negligible effects on transcriptome of oocytes. This experiment was carried out to compare the gene expression profiles of FG vs. VG and FM vs. VM (Fig. 1a). No DEGs were identified between




Figure 3. Vitrification has negligible Effects on transcriptome of oocytes. The Volcano plot (a) shows no DEGs identified in FG vs. VG, indicating that *in vitro* maturation of oocytes vitrified in the GV stage did not cause significant changes in transcriptome profiles when compared with those of fresh oocytes matured *in vitro*. The Volcano plot (b) shows that no DEGs were identified in FM vs. VM, indicating that vitrification did not change the transcriptome profile of MII stage oocytes matured *in vivo*. *Atp5e*, *Atp5o*, *Timm17a* and *Tomm40* in FG vs. VG (c) and *Atp5e*, *Atp5o*, *Ndufb9* and *Uqcrq* in FM vs. VM (d) were randomly selected and examined with qRT-PCR. The expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data. Cyan represents FG group, gray represents VG group, red represents FM group, green represents VM group.

FG and VG, indicating that *in vitro* maturation of oocytes vitrified in the GV stage did not cause significant changes in the transcriptome profile compared with fresh oocytes matured *in vitro* (Fig. 3a). Additionally, there were no DEGs between FM and VM, indicating that vitrification did not change the transcriptome profile of MII stage oocytes matured *in vivo* (Fig. 3b). When some genes were randomly selected in DEGs of FG vs. VG and FM vs. VM and were examined with qRT-PCR, the results showed that the expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data (Fig. 3c and d).

The MII stage is more suitable for oocyte vitrification from the view of transcriptome. Our results showed that no DEGs were found in FM vs. VM; however, 18 DEGs were identified in VG vs. FM, indicating that the transcriptome profile of oocytes vitrified in the MII stage was more similar to those of oocytes matured *in vivo* (Fig. 4a, Table S4). However, 252 DEGs were identified between VG and VM (Table S5), of which 229 were up-regulated and 23 were down-regulated (Fig. 4b). GO analysis of 212 annotated genes of the 252 total DEGs found that the most significant enrichment term is “inner mitochondrial membrane protein complex”, which has 22 genes, including *Atp5o*, *Tomm40* and *Timm13* (Figure S2a). In molecular function category, most terms correlated with NADH activity (Figure S2b). The term “mitochondrial transmembrane transport” was significantly enriched in biological processes category, which included 5 genes: *Tomm40*, *Timm13*, *Timm17a*, *Atp5o* and *Dnlz* (Fig. 4d, Table S6). The differentially expressed genes *Atp5e*, *Dppa5a*, *Haf3a*, *Timm13* in VG vs. VM and *Dppa5a* in VG vs. FM were randomly selected and examined by qRT-PCR; the expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data (Fig. 4c, Figure S3).

Mitochondrial membrane protein gene expression differs between *in vitro* maturation of fresh and vitrified GV stage oocytes. Only 18 DEGs were identified in VG vs. FM, which is lower than the number of DEGs in FG vs. FM, which have 69 DEGs. There were 15 overlapped DEGs between FG vs. FM and VG vs. FM, 54 specific DEGs in FG vs. FM and 3 specific DEGs in VG vs. FM. It seems that VG did behave more




Figure 4. The transcriptome profiles have a significant difference in MII oocytes obtained from GV or MII vitrification. The Volcano plot (a) shows 18 DRGs were identified in VG vs. FM. Red dots represent 17 up-regulated genes, green dots represent 1 down-regulated gene, and blue dots represent the genes that were not differentially expressed in VG vs. FM. The Volcano plot (b) shows a total of 252 genes that were differentially expressed in VG vs. VM. Red dots represent 229 up-regulated genes, green dots represent 23 down-regulated genes, and blue dots represent the genes that were not differentially expressed in VG vs. VM. (c) *Atp5e*, *Dppa5a*, *H3f3a* and *Timm13* were randomly selected and examined by qRT-PCR. The expression of these genes was consistent with the differential expression patterns observed in the RNA-seq data. Gray represents VG group, green represents VM group. (d) The significant GO categories were related to biological process. The number of genes in each term is shown to the right of the corresponding bar.

transcriptomically like the oocytes matured *in vivo* (Fig. 5a). Protein-protein interaction (PPI) analysis was performed to identify the interactions between DEGs. No interaction were identified between DEGs in VG vs. FM, however, interactions were identified between 12 DEGs in FG vs. FM. All of the 12 DEGs were up-regulated and were mitochondrial membrane protein genes. Among them, *Cox4i1* was the only DEGs that belong to the 15 overlapped DEGs. Additionally, the ATP synthase genes *Atp5e* and *Atp5o* were in the key position of the PPI network (Fig. 5b). These results indicated that the mitochondrial membrane protein gene expression was different between *in vitro* maturation of fresh and vitrified GV stage oocytes when compared to FM.

Discussion

RNA-seq does not require pre-designed probes and can detect and quantify entire transcripts, including unknown transcripts¹⁹; it therefore greatly facilitates the study of the influence of *in vitro* maturation and/or vitrification on mouse oocyte gene expression profiles.

In this study, most of the DEGs were up-regulated after IVM, which is in accordance with previous studies showing that most DEGs were up-regulated in human oocytes matured *in vitro* compared with those matured *in vivo*^{4,20}. However, the suboptimal quality of the material (oocytes failed to fertilize in most cases) and uncontrolled variables in those studies make it difficult to interpret the data. To avoid these limitations, we used mouse oocytes to analyse the influence of IVM on oocytes. In our results, *Atp5e* and *Atp5o* were in the top 10 significant DEGs in FG vs. FM and were also in the most significantly enriched GO term of “mitochondrial membrane part”




Figure 5. Mitochondrial membrane protein gene expression is different between *in vitro* maturation of fresh and vitrified GV oocytes. Venn diagram (a) shows 15 overlapping DEGs in FG vs. FM and VG vs. FM; 54 specific DEGs only occur in FG vs. FM, and 3 DEGs only occur in VG vs. FM. (b) Protein-protein interaction networks of the DEGs in FG vs. FM and VG vs. FM. No interaction were identified between DEGs in VG vs. FM, however, interactions were identified between 12 DEGs in FG vs. FM. All of the 12 DEGs were up-regulated and were mitochondrial membrane protein genes. Among them, *Cox4i1* was the only DEGs that belong to the 15 overlapped DEGs (Fig. 5a). The triangle represents the only interacted DEGs (*Cox4i1*) which belong to the 15 overlapped DEGs (Fig. 5a). Size of the circle is proportional to the number of DEGs interacted with it, the color represents Log₂FoldChange in expression levels of differentially expressed genes between FG and FM. The network indicates that *Atp5e* and *Atp5o* play key roles in the PPI network.

and “hydrogen ion transmembrane transport” (Table S2, Fig. 2b), which indicated that *Atp5e* and *Atp5o* may play an important role in the *in vitro* maturation of oocytes. *Atp5e* and *Atp5o* were correlated with ATP synthase. *Atp5e* encodes the ϵ subunit, which is an essential subunit in the biosynthesis and assembly of the F1 portion of ATP synthase²¹. *ATP5o*, located in the stalk of the ATP synthase complex, appears to connect the catalytic core (F1 subunit) and the membrane proton channel (F0 subunit)²². This result may explain why the ATP content was significantly increased during the *in vitro* maturation of mouse oocytes²³. It has been reported that oocytes with higher concentration of ATP have significantly higher fertilization and blastocyst rates²⁴. Thus, *Atp5e* and *Atp5o* may play an important role in increasing the ATP level during the *in vitro* maturation of oocytes and may be important biomarkers for oocytes matured *in vitro*.

It seems the influence of vitrification on the transcriptome is negligible, as no DEGs were found between the FG and VG (Fig. 3a) or FM and VM groups (Fig. 3b). These findings differ from previous studies that reported decreased mRNA expression in vitrified human MII stage oocytes as assessed using traditional reverse transcription-PCR²⁵ and DNA microarray²⁶. However, many of the oocytes they used were unfertilized MII stage oocytes after ICSI, and the time of oocyte collection varied. Recently, a study using RNA-seq showed that vitrification of bovine oocytes matured *in vitro* exhibited changes in the expression of some genes; however, the oocytes they used came from bovine ovaries obtained from a local abattoir²⁷, and the different genetic background among these oocytes should not be ignored. In this study, oocytes obtained from CD-1 mice (all of the same genetic background), could better explore the influence of vitrification, and no significant difference in the transcription of oocytes after vitrification was found. To some extent, these results are consistent with a previous report that vitrified oocytes from the same cohort of donor oocytes (oocytes from same donor(s)) and showed no statistically significant differences in fertilization, embryo quality or clinical results when compared with fresh oocytes^{28–30}.

However, it seems that oocytes vitrified at the GV or MII stage have different transcriptome profiles. In this study, we found that the largest transcriptional difference between VG and VM was mitochondrial function, especially NADH activity (Figure S2b). We found that *Ndufa2*, *Ndufa5*, *Ndufa7*, *Ndufb7*, *Ndufb9* and *Ndufs7* were enriched in all of the terms related to NADH activities. All of these genes were up-regulated and related to NADH dehydrogenase activity, and are in accordance with previous results showing that the ratio of FAD/NAD(P)H is significantly higher in vitrified human oocytes¹⁰. An increased ratio of FAD/NAD(P)H suggests a decreased ATP level in vitrified human oocytes^{9,11}, which can significantly affect spindle integrity and chromosome alignment^{10,12}. *In vitro* matured porcine oocytes obtained from the GV vitrification group exhibited higher abnormal configurations of spindles and chromosomes than oocytes from the MII vitrification group³¹.

In addition, most of the DEGs identified in VG vs. VM were related with mitochondria and their products must undergo transmembrane transport to the mitochondria. *Tomm40*, an important gene for a channel-forming protein involved in the biological process of “mitochondrial transmembrane transport” (Fig. 4d), is essential for the import of protein precursors into the mitochondria. The deletion of *Tomm40* results in the cytosolic

accumulation of unprocessed mitochondrial precursors and subsequent lethality³². Thus, *Tomm40* may be the most promising candidate gene for oocyte viability at different vitrification stages. There have been many reports regarding the various viabilities of oocytes when vitrified in different stages^{33,34}; however, the molecular mechanism of such variability is still unclear. Our results showed no DEGs in FM vs. VM and 18 DEGs in VG vs. FM (Fig. 3b and Fig. 4a), indicating the transcriptome profile of oocytes vitrified in the MII stage was closer to oocytes matured *in vivo*.

Mitochondrial membrane protein gene expression was different between fresh and vitrified GV stage oocytes following *in vitro* maturation. We noted that the number of DEGs in VG vs. FM was lower compared with DEGs in FG vs. FM (Fig. 5a). It appears that *in vitro* maturation allows vitrified GV stage oocytes to recover and behave more transcriptomically like the oocytes matured *in vivo*. The developmental competence of the vitrified-thawed GV stage oocytes (VG), however, was lower than in the *in vitro* matured oocytes (FG)³⁴. Additionally, the abnormal configuration of spindles and chromosomes in mouse cryo-MII group (vitrified at the GV stage, warmed and matured *in vitro*, VG) oocytes (78.9 and 84.2%) was significantly higher than *in vitro*-MII (oocytes matured *in vitro*, FG) oocytes (45.0 and 50.0%, $P < 0.05$)³³. *Atp5e* and *Atp5o*, which both occupy key positions in the PPI network, were up-regulated in FG vs. FM; however, *Atp5e* and *Atp5o* were not up-regulated in VG vs. FM. This finding provides a new explanation for previous results in which the ATP content was significantly lower during *in vitro* maturation of vitrified GV stage oocytes compared with fresh GV stage oocytes³⁵. Low ATP content may result in decreased rates of normal spindle formation¹² which is also correlated with a high aneuploidy rate. Aneuploidy rates in oocytes matured from vitrified-thawed GV stage oocytes (VG) were significantly higher than from *in vitro* matured oocytes (FG) (22.9% vs. 5.8%, respectively; $P < 0.05$)³⁴.

Conclusions

We used RNA-seq and *in silico* pathway analysis to identify DEGs that may be involved in oocyte viability after *in vitro* maturation and/or vitrification. Our results showed the following: 1) *in vitro* maturation influences the mitochondrial membrane protein gene expression, especially those associated with ATP synthase (*Atp5e* and *Atp5o*); 2) oocyte vitrification caused minor or no changes in MII stage oocyte transcriptome profiles; and 3) the MII stage is more suitable for oocyte vitrification from the viewpoint of the transcriptome. This study can contribute to the understanding of the transcriptional regulatory mechanisms, and offer a theoretical basis to further improve the efficiency, of oocytes undergoing *in vitro* maturation and/or vitrification.

Materials and Methods

Ethics statement. The use of the animals and the experimental procedures were approved by the Animal Care Committee at China Agricultural University. The experiment was conducted at China Agricultural University. All methods were carried out in accordance with the approved guidelines.

Reagents. All chemicals and media were purchased from Sigma Chemical Co. (St. Louis, MO, USA), unless otherwise indicated.

Oocyte collection. Oocytes were collected from 8- to 10-week-old CD-1 mice (Vital River Laboratory Animal Technology Co. Ltd. China) as described previously³⁴. The GV oocytes were collected from 8- to 10-week-old mice by ovarian puncture, and then the oocytes were collected by mouth pipette. For *in vitro*-matured MII oocytes, GV oocytes were cultured in M16 medium (foetal bovine serum 50 μ L/mL, follicle stimulating hormone 1 mg/mL, luteotropic hormone 500 μ g/mL, epidermal growth factor 5 μ g/mL and Sodium pyruvate 23 mmol/L) for 18 h, and only oocytes with polar body extrusion were collected. For *in vivo*-matured MII oocyte retrieval, mice were superovulated with 10 IU (intraperitoneal) equine chorionic gonadotropin (eCG; Ningbo Hormone Products Co, China), which was followed 48 hours later by an injection of 10 IU of human chorionic gonadotropin (hCG; Ningbo Hormone Products Co. China). Cumulus-oocyte complexes (COCs) were collected from oviducts at 13 hours after hCG treatment and recovered in M2 medium. Cumulus cells were dispersed by hyaluronidase (300 IU/mL) for 3–5 minutes in M2 medium. Ten mice were used in each case.

Oocyte cryopreservation. *Vitrification solutions.* Pretreatment solution contained 10% dimethylsulfoxide (DMSO) and 10% ethylene glycol (EG) in PBS medium. Vitrification solution (EDFS30) contained 15% DMSO (v:v), 15% EG(v:v), 30% Ficoll (w:v) and 0.5 M sucrose in PBS medium.

Vitrification and warming. Oocytes were vitrified in EDF30 by the open-pulled straws (OPS) method³⁶. First, oocytes were pretreated in pretreatment solution for 30 seconds, transferred to vitrification solution in the narrow end of the OPS, and held for 25 seconds. Then, the straws were immediately plunged into liquid nitrogen (LN2). For thawing, the oocytes were rinsed in 0.5 M sucrose for 5 minutes, then rinsed three times in M2 medium. Over 100 GV oocytes and 100 MII oocytes were collected respectively after thawing.

RNA quantification and qualification. Oocytes were incubated in M2 containing 0.5% pronase for 2–3 min to remove their ZP (zona pellucida). ZP-free oocytes were carefully washed several times with M2. The 100 ZP-free oocytes per group were collected via mouth-pipette and stored in RNA lysis buffer from a SMART-Seq™ v4 Ultra™ Low Input RNA Kit (Clontech laboratories, Inc., CA, USA). The purified total RNA was stored in nuclease-free water, then used for first-strand synthesis. RNA concentration was measured using a Qubit® RNA Assay Kit in a Qubit® 2.0 Fluorimeter (Life Technologies, CA, USA). The results of RNA concentration were shown in Table S1.

cDNA amplification and library preparation for transcriptome sequencing. First-strand cDNA (from total RNA) was synthesized according to the SMART-Seq™ v4 Ultra™ Low Input RNA Kit protocol. The PCR-amplified cDNA was purified using AMPure XP beads, then 1 µl cDNA was validated using an Agilent 2100 Bioanalyzer.

cDNA samples were sheared with a Covaris system before library preparation. Sequencing libraries were generated using a NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (NEB, USA) according to the manufacturer's recommendations. In short, the workflow included conversion of sheared DNA into blunt ends, adenylation of the DNA fragments 3' ends, ligation of index-coded adapters (The Index Primers were shown in Table S7) and PCR amplification. Finally, PCR products were purified (AMPure XP system) and library quality was assessed on an Agilent Bioanalyzer 2100 system (effective concentration of the cDNA libraries >2 nM). These libraries were sequenced using an Illumina HiSeq platform with 150 bp paired-end sequencing at the Novogene Bioinformatics Institute (Beijing, China).

Quality control. Raw data (raw reads) in fastq format were first processed with in-house Perl scripts. In this step, clean data (clean reads) were obtained by removal of reads containing adapter sequences, reads containing poly-N and low quality reads from the raw data. All the downstream analyses were based on clean, high-quality data.

Reads mapping to the reference genome. The reference genome and gene model annotation files were downloaded directly from the genome website (ftp://ftp.ensembl.org/pub/release-79/fasta/mus_musculus/dna/ and ftp://ftp.ensembl.org/pub/release-79/gtf/mus_musculus/). The reference genome index was built using Bowtie v2.2.3, and clean paired-end reads were aligned to the reference genome with TopHat v2.0.12.

Quantification of gene expression levels. HTSeq v0.6.1 was used to count the read numbers mapped to each gene. Then, the FPKM of each gene was calculated on the basis of the length of the gene and read counts mapped to this gene³⁷.

Differential expression analysis. Differential expression analysis was performed using the DESeq R package (1.18.0). DESeq provides statistical routines for determining differential expression in digital gene expression data by using a model based on a negative binomial distribution. The resulting P-values were adjusted using Benjamini and Hochberg's approach for controlling the false discovery rate. Genes with an adjusted P-value < 0.05 as calculated by DESeq were considered differentially expressed.

GO analysis of differentially expressed genes. Differentially expressed genes were called if they satisfied the conditions adjusted P-value < 0.05. Ensemble gene IDs were translated into official gene symbol IDs with BioMart. An analysis of the enrichment of differentially expressed genes was conducted using ClueGO of the Cytoscape software, and P-Values were corrected by the method of Benjamini-Hochberg. A corrected P-value ≤ 0.05 was considered to indicate significant gene enrichment.

PPI analysis of differentially expressed genes. PPI analysis of differentially expressed genes was performed on the basis of the STRING protein interaction database (<http://string-db.org/>). Visual analysis of PPI network data files of differentially expressed genes were created with the Cytoscape software.

qRT-PCR verification. RNA was extracted from 60 oocytes per group utilizing TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. Approximately 0.05 µg RNA was used to synthesize cDNA with an Ambion Cells-to-Complementary DNA II kit (Life Technologies, Inc., Grand Island, NY, USA). qRT-PCR was performed as described previously³⁸ to quantify the mRNA levels of *Atp5e*, *Atp5o*, *Ndufb9*, *Uqcra*, *Timm17a*, *Dppa5a*, *H3f3a*, *Timm13* and *Tomm40*. *Gapdh* was used as a reference gene. Quantitative realtime PCR was performed using the CFX96™ Real-Time PCR Detection System (Bio-Rad) under standard conditions. The expression levels were calculated using the 2^{-DDCt} method described previously³⁹. The primers are shown in Table S8. Each experiment was repeated at least 3 times. All of the data are presented as the means ± SD. The data were analysed by one-way ANOVA using SPSS 20.0 software and p < 0.05 was considered significant.

References

1. Smitz, J. E., Thompson, J. G. & Gilchrist, R. B. The promise of *in vitro* maturation in assisted reproduction and fertility preservation. *Semin Reprod Med.* **29**, 24–37, <https://doi.org/10.1055/s-0030-1268701> (2011).
2. Child, T. J., Phillips, S. J., Abdul-Jalil, A. K., Gulekli, B. & Tan, S. L. A comparison of *in vitro* maturation and *in vitro* fertilization for women with polycystic ovaries. *Obstet Gynecol.* **100**, 665–670 (2002).
3. Gilchrist, R. B. Recent insights into oocyte-follicle cell interactions provide opportunities for the development of new approaches to *in vitro* maturation. *Reprod Fertil Dev.* **23**, 23–31, <https://doi.org/10.1071/rd10225> (2011).
4. Jones, G. M. *et al.* Gene expression profiling of human oocytes following *in vivo* or *in vitro* maturation. *Hum Reprod.* **23**, 1138–1144, <https://doi.org/10.1093/humrep/den085> (2008).
5. Zhang, Z., Liu, Y., Xing, Q., Zhou, P. & Cao, Y. Cryopreservation of human failed-matured oocytes followed by *in vitro* maturation: vitrification is superior to the slow freezing method. *Reprod Biol Endocrinol.* **9**, 156, <https://doi.org/10.1186/1477-7827-9-156> (2011).
6. Cil, A. P. & Seli, E. Current trends and progress in clinical applications of oocyte cryopreservation. *Curr Opin Obstet Gynecol.* **25**, 247–254, <https://doi.org/10.1097/GCO.0b013e32836091f4> (2013).
7. Lockwood, G. M. Social egg freezing: the prospect of reproductive 'immortality' or a dangerous delusion? *Reprod Biomed Online.* **23**, 334–340, <https://doi.org/10.1016/j.rbmo.2011.05.010> (2011).
8. Boggio, A. Italy enacts new law on medically assisted reproduction. *Hum Reprod.* **20**, 1153–1157, <https://doi.org/10.1093/humrep/deh871> (2005).
9. Trapphoff, T. *et al.* Improved cryotolerance and developmental potential of *in vitro* and *in vivo* matured mouse oocytes by supplementing with a glutathione donor prior to vitrification. *Mol Hum Reprod.* **22**, 867–881, <https://doi.org/10.1093/molehr/gaw059> (2016).

10. Nohales-Corcoles, M. *et al.* Impact of vitrification on the mitochondrial activity and redox homeostasis of human oocyte. *Hum Reprod.* **31**, 1850–1858, <https://doi.org/10.1093/humrep/dew130> (2016).
11. Manipalviratn, S. *et al.* Effect of vitrification and thawing on human oocyte ATP concentration. *Fertil Steril.* **95**, 1839–1841, <https://doi.org/10.1016/j.fertnstert.2010.10.040> (2011).
12. Zeng, H. T. *et al.* Low mitochondrial DNA and ATP contents contribute to the absence of birefringent spindle imaged with PolScope in *in vitro* matured human oocytes. *Hum Reprod.* **22**, 1681–1686, <https://doi.org/10.1093/humrep/dem070> (2007).
13. Huang, J. Y., Chen, H. Y., Tan, S. L. & Chian, R. C. Effect of choline-supplemented sodium-depleted slow freezing versus vitrification on mouse oocyte meiotic spindles and chromosome abnormalities. *Fertil Steril.* **88**, 1093–1100, <https://doi.org/10.1016/j.fertnstert.2006.12.066> (2007).
14. Huang, J. Y., Chen, H. Y., Park, J. Y., Tan, S. L. & Chian, R. C. Comparison of spindle and chromosome configuration in *in vitro*- and *in vivo*-matured mouse oocytes after vitrification. *Fertil Steril.* **90**, 1424–1432, <https://doi.org/10.1016/j.fertnstert.2007.07.1335> (2008).
15. Chang, C. C. *et al.* Impact of phase transition on the mouse oocyte spindle during vitrification. *Reprod Biomed Online.* **22**, 184–191, <https://doi.org/10.1016/j.rbmo.2010.10.009> (2011).
16. Tucker, M. J., Wright, G., Morton, P. C. & Massey, J. B. Birth after cryopreservation of immature oocytes with subsequent *in vitro* maturation. *Fertil Steril.* **70**, 578–579 (1998).
17. Chian, R. C. *et al.* Live birth after vitrification of *in vitro* matured human oocytes. *Fertil Steril.* **91**, 372–376, <https://doi.org/10.1016/j.fertnstert.2007.11.088> (2009).
18. Song, W. Y. *et al.* Clinical outcome of emergency egg vitrification for women when sperm extraction from the testicular tissues of the male partner is not successful. *Syst Biol Reprod Med.* **57**, 210–213, <https://doi.org/10.3109/19396368.2011.566666> (2011).
19. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet.* **10**, 57–63, <https://doi.org/10.1038/nrg2484> (2009).
20. Liu, M. H. *et al.* Ultrastructural Changes and Methylation of Human Oocytes Vitrified at the Germinal Vesicle Stage and Matured *in vitro* after Thawing. *Gynecol Obstet Invest.* **82**, 252–261, [doi:10.1159/000448143](https://doi.org/10.1159/000448143) (2017).
21. Mayr, J. A. *et al.* Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 epsilon subunit. *Hum Mol Genet.* **19**, 3430–3439, <https://doi.org/10.1093/hmg/ddq254> (2010).
22. Devenish, R. J., Prescott, M., Boyle, G. M. & Nagley, P. The oligomycin axis of mitochondrial ATP synthase: OSCP and the proton channel. *J Bioenerg Biomembr.* **32**, 507–515 (2000).
23. Yu, Y., Dumollard, R., Rossbach, A., Lai, F. A. & Swann, K. Redistribution of mitochondria leads to bursts of ATP production during spontaneous mouse oocyte maturation. *J Cell Physiol.* **224**, 672–680, <https://doi.org/10.1002/jcp.22171> (2010).
24. Stojkovic, M. *et al.* Mitochondrial distribution and adenosine triphosphate content of bovine oocytes before and after *in vitro* maturation: correlation with morphological criteria and developmental capacity after *in vitro* fertilization and culture. *Biol Reprod.* **64**, 904–909 (2001).
25. Chamayou, S. *et al.* Consequences of metaphase II oocyte cryopreservation on mRNA content. *Cryobiology.* **62**, 130–134, <https://doi.org/10.1016/j.cryobiol.2011.01.014> (2011).
26. Monzo, C. *et al.* Slow freezing and vitrification differentially modify the gene expression profile of human metaphase II oocytes. *Hum Reprod.* **27**, 2160–2168, <https://doi.org/10.1093/humrep/des153> (2012).
27. Wang, N. *et al.* Effect of vitrification on the mRNA transcriptome of bovine oocytes. *Reprod Domest Anim.* **52**, 531–541, <https://doi.org/10.1111/rda.12942> (2017).
28. Sole, M. *et al.* How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes. *Hum Reprod.* **28**, 2087–2092, <https://doi.org/10.1093/humrep/det242> (2013).
29. Cobo, A. *et al.* Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. *Fertil Steril.* **89**, 1657–1664, <https://doi.org/10.1016/j.fertnstert.2007.05.050> (2008).
30. Trokoudes, K. M., Pavlides, C. & Zhang, X. Comparison outcome of fresh and vitrified donor oocytes in an egg-sharing donation program. *Fertil Steril.* **95**, 1996–2000, <https://doi.org/10.1016/j.fertnstert.2011.02.035> (2011).
31. Rojas, C., Palomo, M. J., Albarracin, J. L. & Mogas, T. Vitrification of immature and *in vitro* matured pig oocytes: study of distribution of chromosomes, microtubules, and actin microfilaments. *Cryobiology.* **49**, 211–220, <https://doi.org/10.1016/j.cryobiol.2004.07.002> (2004).
32. Baker, K. P., Schaniel, A., Vestweber, D. & Schatz, G. A yeast mitochondrial outer membrane protein essential for protein import and cell viability. *Nature.* **348**, 605–609, <https://doi.org/10.1038/348605a0> (1990).
33. Wells, D. & Patrizio, P. Gene expression profiling of human oocytes at different 460 maturational stages and after *in vitro* maturation. *Am J Obstet Gynecol.* **198**, 455.e451–459; discussion **455**, e459–411, [doi:10.1016/j.ajog.2007.12.030](https://doi.org/10.1016/j.ajog.2007.12.030) (2008).
34. Cheng, J. *et al.* Effects of vitrification for germinal vesicle and metaphase II oocytes on subsequent centromere cohesion and chromosome aneuploidy in mice. *Theriogenology.* **82**, 495–500, <https://doi.org/10.1016/j.theriogenology.2014.05.009> (2014).
35. Zhao, X. M. *et al.* Recovery of mitochondrial function and endogenous antioxidant systems in vitrified bovine oocytes during extended *in vitro* culture. *Mol Reprod Dev.* **78**, 942–950, <https://doi.org/10.1002/mrd.21389> (2011).
36. Vajta, G. *et al.* Open Pulled Straw (OPS) vitrification: a new way to reduce cryoinjuries of bovine ova and embryos. *Mol Reprod Dev.* **51**, 53–58, [https://doi.org/10.1002/\(sici\)1098-2795\(199809\)51:1<53::aid-mrd6>3.0.co;2-v](https://doi.org/10.1002/(sici)1098-2795(199809)51:1<53::aid-mrd6>3.0.co;2-v) (1998).
37. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol.* **28**, 511–515, <https://doi.org/10.1038/nbt.1621> (2010).
38. Su, Y. Q. *et al.* Oocyte regulation of metabolic cooperativity between mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol biosynthesis in cumulus cells. *Development.* **135**, 111–121, <https://doi.org/10.1242/dev.009068> (2008).
39. Su, Y. Q. *et al.* Selective degradation of transcripts during meiotic maturation of mouse oocytes. *Dev Biol.* **302**, 104–117, <https://doi.org/10.1016/j.ydbio.2006.09.008> (2007).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No.31101714 & No. 31372307); G.X. Jia was supported by CAS “Light of West China” Program. We thank Nature Research Editing Service (NRES) for proofreading the manuscript.

Author Contributions

Xiangwei Fu, Gongxue Jia and Lei Gao designed and organized this research. Gongxue Jia and Lei Gao performed the *in vitro* maturation and vitrification procedures and extracted total RNA from the samples. Lei Gao, Haojia Ma and Zhengyuan Huang performed qRT-PCR experiment. Lei Gao and Ai Li analysed the obtained data. Xiangwei Fu, Shien Zhu, and Yunpeng Hou interpreted the results. Xiangwei Fu and Lei Gao wrote the manuscript. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-13381-5>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017